Il 25 Gennaio 2025 sii terrà presso L'NH Hotel CityLife il primo SINT, meeting cardiologico che promuove il concetto di SINERGISMO tra terapia medica e procedure interventistiche. Vi aspetto
https://t.co/54Kj6WEcHP
#AHA24: How does the benefit of microaxial flow pumps in cardiogenic shock vary by age? In a new analysis of the DanGer Shock trial, Dr. Jacob Møller & team at @CardResearchOuh find that these devices may not benefit older patients (>77 y/o) https://t.co/Qh90qSBgLZ
#JACC #cvGeri #STEMI
#TCT2024 Is it time to get rid of cause specific hospitalization as an endpoint?
2 trials showing TAVR reduces CV hosp (EARLY TAVR) and unplanned aortic hospitalization (EVOLVED) with the former hitting a primary composite driving by this cause specific endpoint.
First prospective study at Johns Hopkins on >1000 pts w/ #echofirst and #RHC data to define grades of severity of echo-based measures of RV dysfunction in PH population @CircImaging
https://t.co/IRN2jG73bh
Few learning points:
❗️degree of RV dysfx -> worse outcome & symptoms
❗️echo thresholds to define mild/moderate/severe RV dysfx in PH patients based on percentiles are now available
❗️FAC, RVFWLS, and RVGLS were independently associated with outcomes, whereas TAPSE was not
❗️TAPSE remained normal except when PVR≥7 WU, and even then, was only mildly reduced (1.6±0.4 cm)
❗️RVGLS <20% in PH pts increased mortality risk
❗️TAPSE/PASP and FAC/PASP decreased with increasing PVR
❗️moderately vs mildly decreased TAPSE/PASP has a 37% increased risk of death
Congratulations, @MMukherjeeMD@LunaGargani@Ivan_Echocardio@lpbadano@NAjmoneMarsan@leylaelifsade@DonalErwan@VDelgadoGarcia@CaravitaSergio@hahn_rt@robertomlang
The #EAPCI Core Curriculum for Percutaneous Valvular & Structural Heart Intervention
Published in @EuroInterventio on the occasion of #ESCCongress 2024
Significant work from the #EAPCI Training & Certification Committee and collaborators.
https://t.co/ZngWhmV2y4
Lower plasma ferritin levels are linked to an increased risk of heart failure & diastolic dysfunction in older adults, regardless of anemia status. Iron repletion could be key in preventing heart failure. https://t.co/X53t58Rcdj
#JACCHF#HeartFailure#ARIC#Anemia
In a large population of up to 1,000 US and European patients with intermediate- and high-risk pulmonary embolism, mechanical thrombectomy using the FlowTriever System was evaluated without a specified comparison group. The study demonstrated a favourable safety profile, with major adverse events in 1.8% of patients, and low all-cause mortality rates at 48 hours (0.3%) and 30 days (0.8%). Significant improvements were noted in haemodynamics and dyspnoea, and a majority of patients avoided overnight ICU stay post-procedure, over the course of 48 hours and 30 days following the intervention. #EIJBestOf https://t.co/oKuRZ5xQvC
The use of DOACs after TMVR, compared with VKAs, appears to reduce the risk of bleeding complications and decrease the length of hospital stay for patients, without a significant increase in the risk of thrombotic events.
https://t.co/QPeoOFhpUa
After mitral valve repair, women have a higher risk for all-cause mortality at lower LVESD and LVESDi and higher EF. We should consider sex-specific thresholds for LVESDi in surgical decision making in patients with severe MR. https://t.co/l1XknT3ZSS
Optimization of valve expansion for TMVR. Degenerated 27mm Magna w sev stenosis, pre-fractured with 28mm 🎈. 29mm S3 implanted, further post-dilated on atrial side to improve expansion. No post gradient, no leak. Paced OTW. Sentinel captured calcific debries. CT neo-LVOT 321.
DAPAglofazin Safe in AMI pts without DM, important metabolic benefits for these patients
@AHAScience#AHA23@American_Heart
Dr. Stefan James Presenting:
THE WINS are in favor of DAPA
Following a pos ad board, FDA just approved renal denervation with the Recor ultrasound energy-based Paradise system. No word yet on the Medtronic radiofrequency energy-based Spyral system which received a neg ad board review. From our recent JACC editorial results looks similar.